Effect of Unani drugs in Acidity
- Conditions
- Health Condition 1: K318- Other specified diseases of stomach and duodenum
- Registration Number
- CTRI/2020/04/024500
- Lead Sponsor
- ational Institute of Unani Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Symptoms persist at least for 1 month with moderate to severe symptoms (score > 4 on the 7 point Global overall symptoms (GOS) scale).
1.Patients age below 18 and above 50 year
2.Patients with severe systemic and metabolic diseases
3.History of angina pectoris
4.Pregnant and lactating women
5.Patients with alarming symptoms (unintentional weight loss, recurrent vomiting, dysphasia, hematemesis, Malena, fever, jaundice, anemia.
6.History of any serious gastrointestinal disease including peptic ulcer, malignancy, dysmotility.
7.Previous endoscopic diagnosis of erosive gastro-esophagitis or Barrett esophagus.
8.Gastrointestinal surgery within 30 days.
9.Hemoglobin <9g/dl, Total leukocyte count <3000/ul, Platelet count <75000/ul, AST & ALT >120 IU/L, Serum creatinine >1.5 mg/dl, Occult blood in stool.
10.Treatment history of NSAIDs, H2 receptors blockers, PPI, Prokinetic drugs, sucralfate or other ulcer healing agents within 15 days prior to enrolment.
11.Concomitant use of psychotropic drugs.
12.History of alcohol consumption
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method GOS (Global over all symptoms) scaleTimepoint: 0th , 7th, 14th, 21st and 28th Day
- Secondary Outcome Measures
Name Time Method 1.Changes in the clinical global impression (CGI) scale score22 <br/ ><br>2.Unani Medicine Symptom Score5 (SS) <br/ ><br>Timepoint: 0th , 7th, 14th, 21st and 28th Day